Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

ATYR vs CCCC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ATYR Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 4–4 Matrix Metrics)

ATYR Overall Winner 6-Pillar Tally: ATYR 3 – 2 CCCC (1 Tie) Matrix Metrics: ATYR 4 – 4 CCCC

As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) is the stronger overall head-to-head candidate over C4 Therapeutics, Inc. (CCCC) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ATYR carries a Unified Composite Score of 34.3/100 (SELL) at $4.96 (N/M Forward P/E, 0.0% operating margin), whereas CCCC carries 47.7/100 (HOLD) at $2.56 (N/M Forward P/E, -315.9% operating margin).

  • Composite vs. Pillar Nuance: While CCCC currently prints a higher short-term Unified Composite Score (47.7/100 HOLD vs. ATYR 34.3/100 SELL), ATYR captures the overall institutional head-to-head verdict (4–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -315.9% operating margin) and revenue trajectory (+0.0% vs. -24.6% YoY).
  • Technical & Structure Timing Caution: ATYR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 57.6); meanwhile CCCC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ATYR vs CCCC
ATYR NASDAQ Head-to-Head Winner
aTyr Pharma, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$4.96
-5.34% 1D
Market Cap $15.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -9.67β · 13806% Vol
Unified Composite Score
34.3 / 100 SELL
Tech 50.0 Fund 36.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (391.4% over 20 days), RSI 58
RSI-14: 57.6 · SMA20: $4.36 · SMA50: $1.92
CCCC NASDAQ
C4 Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$2.56
-3.58% 1D
Market Cap $362.4M
TTM Revenue $32M
Forward P/E N/M
Beta / 30D Vol 1.46β · 67% Vol
Unified Composite Score
47.7 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 64.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.8%), weak momentum, RSI 34
RSI-14: 34.2 · SMA20: $3.05 · SMA50: $3.09

6-Pillar Scorecard Institutional Category Breakdown (ATYR 3 – 2 CCCC)

Columns: Metric · ATYR · CCCC
1. Valuation Multiples CCCC
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 11.9x
2. Growth & Scale CCCC
Revenue Growth (YoY) +0.0% -24.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $32M
Market Cap $15.6M $362.4M
3. Profitability & Quality ATYR
Gross Margin N/A 88.8%
Operating Margin 0.0% -315.9%
Net Profit Margin 0.0% -282.2%
Return on Equity (ROE) -93.7% -47.6%
4. Balance Sheet & Cash Flow ATYR
Cash Generation (TTM) N/A -$80M
Cash Flow Margin N/A N/A
Net Cash / Leverage $4.9M Net Cash $23M Net Debt (0.24x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ATYR
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 154.5% (36th %ile) 79.8% (3rd %ile)
Put/Call OI Skew N/A 0.41x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ATYR (4) vs CCCC (4)
Institutional Metric ATYR CCCC Criterion Row Edge
Market Capitalization
Scale
$15.6M $362.4M Larger Scale CCCC
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -24.6% Higher Growth ATYR
Operating Margin (TTM)
Profitability
0.0% -315.9% Higher Margin ATYR
Net Profit Margin
Profitability
0.0% -282.2% Higher Margin ATYR
Return on Equity (ROE)
Capital Efficiency
-93.7% -47.6% Higher ROE CCCC
52-Week Range Position
Momentum
62% ($0–$8) 25% ($2–$5) Stronger Trend ATYR
Beta / 30D Volatility
Risk Regime
-9.67β · 13806% Vol 1.46β · 67% Vol Lower Realized Risk CCCC
Unified Institutional Score
Composite Signal
34.3 / 100 (SELL) 47.7 / 100 (HOLD) Higher Composite CCCC
Trailing 12M Revenue (USD)
Operating Scale
N/A $32M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 88.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 11.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($4.9M Net Cash) -$80M ($23M Net Debt (0.24x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ATYR +2800.35 pp
ATYR: +2788.76% · CCCC: -11.59%
3M Horizon ATYR +870.24 pp
ATYR: +830.93% · CCCC: -39.31%
6M Horizon ATYR +944.77 pp
ATYR: +926.92% · CCCC: -17.85%
1Y Horizon ATYR +555.26 pp
ATYR: +558.7% · CCCC: +3.44%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ATYR Revenue CCCC Revenue ATYR Op. Margin CCCC Op. Margin Margin Leader
FY2019 $0M N/A -5445.0% N/A ATYR
FY2020 $10M N/A -152.2% N/A ATYR
FY2021 N/A $50M N/A -179.4% CCCC
FY2022 $10M $30M -446.8% -416.6% CCCC
FY2023 $0M $20M -15557.8% -669.8% CCCC
FY2024 $0M $40M -28899.6% -336.1% CCCC
FY2025 $0M $40M -40856.3% -320.5% CCCC

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ATYR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 154.5%
IV Percentile 36th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ATYR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CCCC BREAKDOWN
118d in phase · OBV DISTRIBUTION
Current IV 79.8%
IV Percentile 3rd %ile
Put/Call OI Skew 0.41x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact CCCC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ATYR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CCCC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $362.4M market capitalization and -315.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ATYR vs CCCC Key Questions & Quantitative Answers

As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) is the stronger overall head-to-head candidate over C4 Therapeutics, Inc. (CCCC) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ATYR carries a Unified Composite Score of 34.3/100 (SELL) at $4.96 (N/M Forward P/E, 0.0% operating margin), whereas CCCC carries 47.7/100 (HOLD) at $2.56 (N/M Forward P/E, -315.9% operating margin). Composite vs. Pillar Nuance: While CCCC currently prints a higher short-term Unified Composite Score (47.7/100 HOLD vs. ATYR 34.3/100 SELL), ATYR captures the overall institutional head-to-head verdict (4–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -315.9% operating margin) and revenue trajectory (+0.0% vs. -24.6% YoY). Technical & Structure Timing Caution: ATYR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 57.6); meanwhile CCCC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CCCC leads the Growth & Scale pillar: ATYR posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CCCC at -24.6% YoY revenue growth and +0.0% YoY earnings growth on $32M TTM revenue (88.8% gross margin, -315.9% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), ATYR cumulative revenue shifted +0.0% while CCCC shifted -20.0%. In operating R&D and SG&A reinvestment, ATYR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CCCC.

CCCC screens cheaper on headline valuation multiples. ATYR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CCCC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 11.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ATYR (-93.7% ROE) versus CCCC (-47.6% ROE) capital efficiency.

In options market volatility and institutional positioning, ATYR carries 154.5% implied volatility (36th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-9.67β · 13806% Vol realized risk). By comparison, CCCC carries 79.8% implied volatility (3rd %ile, Compressed (<25th %ile)), a 0.41x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.46β · 67% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.